• Ciclesonide and the Next Logic of Respiratory Research

  2026-08-24

  Ciclesonide illustrates how prodrug activation, glucocorticoid receptor binding, and lung-cell pharmacology can be converted into a disciplined translational strategy. This article examines the established respiratory evidence for Ciclesonide alongside the emerging ERAD-engaging chimera platform, while clearly separating validated biology from forward-looking hypotheses.

• Nintedanib in ATRX-Deficient Glioma Research

  2026-08-23

  Nintedanib (BIBF 1120) combines VEGFR, FGFR, and PDGFR blockade for studying angiogenesis, tumor-cell vulnerability, and fibrosis-related signaling. This workflow translates ATRX-stratified glioma findings into practical dose-response, apoptosis, combination, and troubleshooting strategies.

• Disulfiram and Synthetic Lethality in Cancer

  2026-08-22

  Disulfiram is emerging as more than a repurposed anti-alcoholism drug: its ALDH2 inhibition, copper-linked proteasome effects, and ROS-driven apoptotic signaling create a compelling framework for genotype-informed cancer research. This article translates recent APC-deficient colorectal cancer findings into practical workflow and translational strategy.

• PPP1R3G/PP1γ Control RIPK1-Driven Cell Death

  2026-08-21

  The reference study identifies PPP1R3G as a regulatory subunit that recruits PP1γ to dephosphorylate and activate RIPK1, thereby promoting RIPK1-dependent apoptosis and type I necroptosis. Genetic, pharmacological, and in vivo experiments connect this phosphatase axis to TNF-induced systemic inflammation and provide a framework for dissecting cell-death decisions.

• Carbapenemase Gene Transfer in CREC: Guangdong Study

  2026-08-20

  Chen et al. combine gene localization, antimicrobial susceptibility testing, conjugation, mobile-element profiling, and ERIC-PCR to examine carbapenem-resistant Enterobacter cloacae across multiple teaching hospitals. Their findings emphasize plasmid-associated blaNDM-1, efficient in vitro transfer, and the coexistence of horizontal mobility with possible clonal dissemination.

• Salinomycin Workflows for HCC Research

  2026-08-20

  Salinomycin combines ion transport, ABC drug transporter modulation, Wnt/β-catenin suppression, and apoptosis readouts in one research workflow. This guide translates those properties into practical HCC assays, concentration planning, calcium measurements, orthogonal validation, and troubleshooting safeguards.

• Clodronate Liposomes: Reliable In Vivo Workflows

  2026-08-19

  This scenario-based guide explains how Clodronate Liposomes, SKU K2721, can improve interpretation of macrophage-dependent viability, proliferation, and cytotoxicity experiments. It covers mechanism, controls, administration planning, readout validation, and practical vendor-selection criteria using product documentation and current macrophage-immunology evidence.

• Berberine, SIRT6–AMPK, and Atrial Fibrillation

  2026-08-19

  The reference study identifies impaired SIRT6–AMPK signaling as a contributor to angiotensin II-induced atrial remodeling and links this defect to NLRP3 inflammasome activation. Using human atrial samples, bioinformatics, and mechanistically controlled mouse experiments, the authors show that berberine reduces atrial fibrosis and vulnerability to atrial fibrillation in a SIRT6-dependent manner.

• Vorinostat and the Logic of Apoptosis Assays

  2026-08-18

  Vorinostat, also called suberoylanilide hydroxamic acid, is more than a conventional HDAC inhibitor: it is a powerful probe for separating chromatin remodeling from active mitochondrial death signaling. This article translates new RNA Pol II biology into more discriminating cancer biology research and apoptosis assay design.

• Annexin V-PE Reagent for CAR-T Apoptosis Studies

  2026-08-18

  Use the Annexin V-PE Reagent to convert phosphatidylserine exposure into a rapid, quantifiable readout of early apoptosis, target-cell killing, and potential CAR-T fratricide. Its one-step fluorescence workflow supports both flow cytometry and microscopy, making it practical for comparing CD38 binder designs and optimizing immune-cell assays.

• Mubritinib–HSA Binding: Methods and Findings

  2026-08-17

  The reference study integrates multispectroscopic measurements, biochemical testing, and molecular docking to define how mubritinib binds human serum albumin and modifies its function. Its findings support a moderately affine interaction at Sudlow site I, while illustrating why plasma-protein binding should be evaluated alongside a drug’s intended molecular target.

• 14-3-3 Binding Proteins ATG9A and PTOV1 in Cancer

  2026-08-17

  The reference study identifies ATG9A and PTOV1 as previously unrecognized 14-3-3-interacting proteins and connects them to basal autophagy, protein turnover, oncogenic signaling, and cancer-relevant regulation. Its combination of BioID proteomics, quantitative whole-proteome analysis, and biochemical validation provides a useful framework for distinguishing proximity, binding, phosphorylation, and functional consequences.

• Müller Cell PEDF Links Angiopoietins to Retinal Survival

  2026-08-16

  Younis and colleagues show that angiopoietin-dependent retinal neuroprotection is mediated substantially through Müller cells rather than by a direct effect on neuronal cultures alone. Their data connect Müller cell Tie-2–PI3K/Akt signaling with pigment epithelium-derived factor (PEDF) production, providing a mechanistic framework for studying neurovascular interactions under hypoxia.

• Acetylcholine Chloride in Gut-Brain Research

  2026-08-15

  Acetylcholine Chloride provides a defined cholinergic comparator for testing how gut microbes influence vagal and brain signaling. This practical guide covers formulation, ex vivo and cellular workflows, assay controls, and troubleshooting for translational neuroscience studies.

• 4-Ethylphenyl Sulfate: Assay Workflows

  2026-08-15

  A scenario-based guide to using 4-Ethylphenyl sulfate (SKU B6051) in cell viability, gut-brain, and renal biomarker workflows. It explains formulation, exposure design, assay controls, interpretation, and practical vendor-selection criteria using product specifications and peer-reviewed uremic-toxin data.

452 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page